Notably, bevacizumab demonstrated a lower signal for certain SOCs compared to temozolomide, including “pregnancy, puerperium and perinatal conditions” (ROR = 0.27, 95% CI: 0.11–0.67), “blood and lymphatic system disorders” (ROR = 0.39, 95% CI: 0.37–0.42), and “ear and labyrinth disorders” (ROR = 0.61, 95% CI: 0.39–0.95). Here, CISH is linked to lymphatic system disorder.